Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2003

View Archived Issues

NeoPharm to resume LEP clinical trials

Antitumor protein tyrosine kinase inhibitors newly identified at Pfizer

New analgesic agents in early development at Gruenenthal

Merck researchers describe new DPP-IV inhibitors for diabetes and other disorders

Antiarrhythmic benzopyran derivatives prepared and tested at Nissan Chemical

NPS updates clinical progress

Atheroprotective effects of statins

FK-960 distribution evaluated in rhesus monkeys

Revotar and Texas Biotechnology amend bimosiamose license agreement

BioCryst refocuses resources following termination of peramivir agreement

Rigel reports accomplishments in 2002 and outlook for 2003

Pilot study for DB-289 completes enrollment

Phase II/III trial planned for iseganan for prevention of VAP

Metvix launched in Germany

FDA approves Avonex for early MS

Merck & Co. discontinues development of GABA agonist

MIV-210 enters phase I study of multiple oral doses

Fludara receives E.U. approval as first-line treatment for B-CLL

Wyeth presents various series of PAI-1 inhibitors

New ORL1 modulators in early development at Pfizer

Raptiva enters phase II trial in psoriatic arthritis

Novo Nordisk updates progress of R&D portfolio

First potent human MC1 receptor antagonist disclosed in recent article

Clinical toxicity and pharmacokinetics determined for lead alkycycline

Beneficial effects for SAR-943 on inflammation and remodeling in murine asthma model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...